These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26216068)

  • 41. Immunology of hepatitis B and hepatitis C virus infections.
    Boonstra A; Woltman AM; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1049-61. PubMed ID: 19187866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood T, B, and NK cells in relation to histological hepatitis activity and fibrosis stage in chronic hepatitis C.
    Panasiuk A; Prokopowicz D; Zak J; Wysocka J
    Hepatogastroenterology; 2003; 50(49):178-82. PubMed ID: 12630018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathophysiology of hepatitis C virus infection and related liver disease.
    Pawlotsky JM
    Trends Microbiol; 2004 Feb; 12(2):96-102. PubMed ID: 15036326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Up-regulation of FOXP3 and induction of suppressive function in CD4+ Jurkat T-cells expressing hepatitis C virus core protein.
    Dominguez-Villar M; Fernandez-Ponce C; Munoz-Suano A; Gomez E; Rodríguez-Iglesias M; Garcia-Cozar F
    Clin Sci (Lond); 2012 Jul; 123(1):15-27. PubMed ID: 22214248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.
    Nagai S; Yoshida A; Kohno K; Altshuler D; Nakamura M; Brown KA; Abouljoud MS; Moonka D
    Hepatology; 2014 Jan; 59(1):35-45. PubMed ID: 23728831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis.
    Krämer B; Körner C; Kebschull M; Glässner A; Eisenhardt M; Nischalke HD; Alexander M; Sauerbruch T; Spengler U; Nattermann J
    Hepatology; 2012 Oct; 56(4):1201-13. PubMed ID: 22532190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virology and pathogenesis of hepatitis C virus recurrence.
    Ramírez S; Pérez-Del-Pulgar S; Forns X
    Liver Transpl; 2008 Oct; 14 Suppl 2():S27-35. PubMed ID: 18825723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CCL5: a double-edged sword in host defense against the hepatitis C virus.
    Katsounas A; Schlaak JF; Lempicki RA
    Int Rev Immunol; 2011; 30(5-6):366-78. PubMed ID: 22053974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation.
    Weston SJ; Leistikow RL; Reddy KR; Torres M; Wertheimer AM; Lewinsohn DM; Chou S; Davey MP; Corless C; O'Farrelly C; Nelson DR; Rosen HR
    Hepatology; 2005 Jan; 41(1):72-81. PubMed ID: 15619226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C virus--T-cell responses and viral escape mutations.
    Petrovic D; Dempsey E; Doherty DG; Kelleher D; Long A
    Eur J Immunol; 2012 Jan; 42(1):17-26. PubMed ID: 22125159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C core antibody detection in acute hepatitis and cirrhosis patients from Tunisia.
    Coursaget P; Simpson B; el Goulli N; Ben Khelifa H; Kastally R
    Pathol Biol (Paris); 1992 Jun; 40(6):646-8. PubMed ID: 1383914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C.
    Self AA; Losikoff PT; Gregory SH
    Hum Vaccin Immunother; 2013 Jul; 9(7):1569-76. PubMed ID: 23732899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease.
    Morita K; Fukuda Y; Nakano I; Katano Y; Hayakawa T
    Hepatogastroenterology; 2005; 52(66):1803-8. PubMed ID: 16334781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apoptosis and progression of hepatic fibrosis in hepatitis C patients.
    Schinoni MI; Paraná R; Cavalcante D
    Braz J Infect Dis; 2006 Apr; 10(2):117-21. PubMed ID: 16878263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection.
    McCaughan GW; Zekry A
    Transpl Infect Dis; 2000 Dec; 2(4):166-85. PubMed ID: 11429029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection.
    Giannelli G; Antonaci S
    Histol Histopathol; 2005 Jul; 20(3):939-44. PubMed ID: 15944944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrent hepatitis C: the bane of transplant hepatology.
    Te HS
    Hepatology; 2014 Jan; 59(1):21-3. PubMed ID: 23813788
    [No Abstract]   [Full Text] [Related]  

  • 58. Mechanisms of hepatic toxicity. IV. Pathogenetic mechanisms involved in hepatitis C virus-inducedliver diseases.
    Lau JY
    Am J Physiol; 1998 Dec; 275(6):G1217-20. PubMed ID: 9843755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of antibodies to hepatitis C in different etiologies of cirrhosis.
    Dény P; Nicolas J; Loiseau D; Lefrère J
    J Hepatol; 1990 Nov; 11(3):393. PubMed ID: 1963179
    [No Abstract]   [Full Text] [Related]  

  • 60. Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activity.
    Heeg M; Thimme R
    Hepatology; 2012 Oct; 56(4):1197-200. PubMed ID: 22610395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.